NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.87

25 May
2022

0.070

OPEN

$3.92

1.84%

HIGH

$3.92

1,834,632

LOW

$3.74

TARGET
$4.343 12.2% upside
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . COH . FPH . IPD . LHC . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY20
Actual		 FY21
Actual		 FY22
Forecast		 FY23
Forecast
EPS (cps) xxx 2.9 - 0.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx - 15.7% N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx 0.0% N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx2.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx101.8 M
Book Value Per Share xxxxxxxxxxxxxxx45.0
Net Operating Cash Flow xxxxxxxxxxxxxxx7.3 M
Net Profit Margin xxxxxxxxxxxxxxx8.42 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx6.60 %
Return on Invested Capital xxxxxxxxxxxxxxx6.54 %
Return on Assets xxxxxxxxxxxxxxx5.48 %
Return on Equity xxxxxxxxxxxxxxx6.60 %
Return on Total Capital xxxxxxxxxxxxxxx6.33 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx6.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.2

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

23/02/2022

5

Sell

$4.00

3.36%

Nanosonics's December first-half met consensus forecasts, and disappointed Citi due to a revenue hit (partly covid driven), and the broker downgrades EPS forecasts -121%, -24% and -18% in FY22, FY23 and FY24.

Citi now forecasts a small FY22 loss, expecting EMEA and APAC sales will take longer than forecast to establish and the general outlook has deteriorated.

Sell rating retained. Target price slides to $4 from $5.

FORECAST
Citi forecasts a full year FY22 dividend of 0.00 cents and EPS of minus -0.90 cents.
Citi forecasts a full year FY23 dividend of 0.00 cents and EPS of 5.30 cents.

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

NAN STOCK CHART

FNArena News on NAN

1
Australian Broker Call *Extra* Edition – May 17, 2022

May 17 2022 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Apr 07, 2022

Apr 07 2022 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 04, 2022

Mar 04 2022 - Daily Market Reports
4
The Short Report – 03 Mar 2022

Mar 03 2022 - Weekly Reports
5
Rudi’s View: Too Many Distractions From Corporate Results

Mar 03 2022 - Rudi's View

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia